ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NK Imerys

26.70
-0.16 (-0.60%)
31 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Imerys EU:NK Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.16 -0.60% 26.70 26.50 26.96 26.96 26.48 26.96 102,804 16:40:00

Jury Awards $110 Million to Plaintiff in Johnson & Johnson Baby Powder Case

05/05/2017 3:18pm

Dow Jones News


Imerys (EU:NK)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Imerys Charts.
By Anne Steele 

Johnson & Johnson was hit with a $110 million jury decision in favor of a woman who said talc in the company's baby powder gave her ovarian cancer, the latest -- and largest -- verdict yet in the litigation saga.

The company said it would quickly appeal the verdict awarded by a St. Louis jury, the fourth such losing case for J&J and Imerys SA, the talc mining company.

A J&J spokeswoman said a jury decision in the company's favor in St. Louis in March and the dismissal of two cases in New Jersey in September 2016 "further highlight the lack of credible scientific evidence behind plaintiffs' allegations." In the New Jersey cases, a state court judge ruled that plaintiffs' scientific experts couldn't adequately support their theories that talcum powder causes ovarian cancer.

J&J has said talc is safe to use in cosmetic products and that its baby-powder labeling is appropriate. The spokeswoman said the company has no plans to settle any related pending litigation.

"We are preparing for additional trials this year and we will continue to defend the safety of Johnson's Baby Powder," she said.

J&J won the most recent trial in March but lost three others, which led to verdicts totaling more than $194 million that are now on appeal. Thursday's verdict in St. Louis in favor of a 62-year-old Virginia woman capped the fifth trial alleging the company's talc is tied to ovarian cancer.

Lawyers for the plaintiff said the litigation continues with "thousands more claimants across the globe."

"We don't care how many trials it takes," said James Onder, one of the trial attorneys, noting that his firm will continue to support those suing the companies "until Johnson & Johnson and Imerys stand up and do the right thing."

Write to Anne Steele at Anne.Steele@wsj.com

 

(END) Dow Jones Newswires

May 05, 2017 10:03 ET (14:03 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Imerys Chart

1 Year Imerys Chart

1 Month Imerys Chart

1 Month Imerys Chart

Your Recent History

Delayed Upgrade Clock